Dysregulated expression of dickkopfs for potential detection of hepatocellular carcinoma

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90
   PubMed Web of Science ®Google Scholar
• Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence. mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27(9):1485-91
   PubMed Web of Science ®Google Scholar
• Kemp W, Pianko S, Nguyen S, et al. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol 2005;20(6):873-81
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362(9399):1907-17
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-50
   PubMed Web of Science ®Google Scholar
• Colombo M. Screening and diagnosis of hepatocellular carcinoma. Liver Int 2009;29(Suppl 1):143-7
   Google Scholar
• Trinchet JC, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011;54(6):1987-97
   PubMed Web of Science ®Google Scholar
• Ikeda K, Saitoh S, Tsubota A, et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993;71(1):19-25
   Google Scholar
• Ciccarelli O, Lai Q, Goffette P, et al. Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria. Transpl Int 2012;25(8):867-75
   Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37(2):429-42
   PubMed Web of Science ®Google Scholar
• Zhang XF, Lai EC, Kang XY, et al. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and a monitor of recurrence of hepatocellular carcinoma after curative liver resection. Ann Surg Oncol 2011;18(8):2218-23
   PubMed Web of Science ®Google Scholar
• Morimoto M, Numata K, Nozaki A, et al. Novel Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low alpha-fetoprotein concentrations. Int J Clin Oncol 2012;17(4):373-9
   Google Scholar
• Shirakawa H, Suzuki H, Shimomura M, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009;100(8):1403-7
   PubMed Web of Science ®Google Scholar
• Marrero JA, Su GL, Wei W, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003;37(5):1114-21
   PubMed Web of Science ®Google Scholar
• Matsubara M, Shiraha H, Kataoka J, et al. Des-gamma-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27(10):1602-8
   Google Scholar
• Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010;59(12):1687-93
   PubMed Web of Science ®Google Scholar
• Sun S, Poon RT, Lee NP, et al. Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (<or=2 cm). J Proteome Res 2010;9(4):1923-30
   Google Scholar
• Chen L, Ho DW, Lee NP, et al. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Ann Surg Oncol 2010;17(9):2518-25
   Google Scholar
• Chon YE, Choi GH, Lee MH, et al. Combined measurement of preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma. Int J Cancer 2012;131(10):2332-41
   Google Scholar
• Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012;2(2):e000825
   PubMed Web of Science ®Google Scholar
• Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010;70(23):9798-807
   PubMed Web of Science ®Google Scholar
• Qu KZ, Zhang K, Li H, et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011;45(4):355-60
   PubMed Web of Science ®Google Scholar
• Fatima S, Lee NP, Luk JM. Dickkopfs and Wnt/beta-catenin signalling in liver cancer. World J Clin Oncol 2011;2(8):311-25
   Google Scholar
• McLin VA, Rankin SA, Zorn AM. Repression of Wnt/beta-catenin signaling in the anterior endoderm is essential for liver and pancreas development. Development 2007;134(12):2207-17
   Google Scholar
• Cadigan KM, Liu YI. Wnt signaling: complexity at the surface. J Cell Sci 2006;119(Pt 3):395-402
   PubMed Web of Science ®Google Scholar
• Suzuki T, Yano H, Nakashima Y, et al. Beta-catenin expression in hepatocellular carcinoma: a possible participation of beta-catenin in the dedifferentiation process. J Gastroenterol Hepatol 2002;17(9):994-1000
   Google Scholar
• Wong CM, Fan ST, Ng IO. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001;92(1):136-45
   PubMed Web of Science ®Google Scholar
• Huang H, Fujii H, Sankila A, et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999;155(6):1795-801
   PubMed Web of Science ®Google Scholar
• Nhieu JT, Renard CA, Wei Y, et al. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999;155(3):703-10
   PubMed Web of Science ®Google Scholar
• Kondo Y, Kanai Y, Sakamoto M, et al. Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma. Jpn J Cancer Res 1999;90(12):1301-9
   Google Scholar
• Inagawa S, Itabashi M, Adachi S, et al. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 2002;8(2):450-6
   Web of Science ®Google Scholar
• Cieply B, Zeng G, Proverbs-Singh T, et al. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009;49(3):821-31
   PubMed Web of Science ®Google Scholar
• Kim M, Lee HC, Tsedensodnom O, et al. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol 2008;48(5):780-91
   Web of Science ®Google Scholar
• Bengochea A, de Souza MM, Lefrancois L, et al. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer 2008;99(1):143-50
   Web of Science ®Google Scholar
• Merle P, de la Monte S, Kim M, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 2004;127(4):1110-22
   Web of Science ®Google Scholar
• Csepregi A, Rocken C, Hoffmann J, et al. APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008;134(5):579-89
   PubMed Web of Science ®Google Scholar
• Lee S, Lee HJ, Kim JH, et al. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003;163(4):1371-8
   PubMed Web of Science ®Google Scholar
• Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000;24(3):245-50
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002;21(31):4863-71
   PubMed Web of Science ®Google Scholar
• Chan DW, Chan CY, Yam JW, et al. Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. Gastroenterology 2006;131(4):1218-27
   Google Scholar
• Yau TO, Chan CY, Chan KL, et al. HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing. Oncogene 2005;24(9):1607-14
   Google Scholar
• Pang R, Yuen J, Yuen MF, et al. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 2004;23(23):4182-6
   PubMed Web of Science ®Google Scholar
• Krupnik VE, Sharp JD, Jiang C, et al. Functional and structural diversity of the human Dickkopf gene family. Gene 1999;238(2):301-13
   PubMedGoogle Scholar
• Glinka A, Wu W, Delius H, et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998;391(6665):357-62
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, et al. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev Cell 2001;1(3):423-34
   Google Scholar
• Semenov MV, Tamai K, Brott BK, et al. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol 2001;11(12):951-61
   PubMedGoogle Scholar
• Yamamoto H, Sakane H, Michiue T, Kikuchi A. Wnt3a and Dkk1 regulate distinct internalization pathways of LRP6 to tune the activation of beta-catenin signaling. Dev Cell 2008;15(1):37-48
   PubMedGoogle Scholar
• Ellwanger K, Saito H, Clement-Lacroix P, et al. Targeted disruption of the Wnt regulator Kremen induces limb defects and high bone density. Mol Cell Biol 2008;28(15):4875-82
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang Y, Li X, et al. Characterization of the Kremen-binding site on Dkk1 and elucidation of the role of Kremen in Dkk-mediated Wnt antagonism. J Biol Chem 2008;283(34):23371-5
   PubMedGoogle Scholar
• Aguilera O, Fraga MF, Ballestar E, et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 2006;25(29):4116-21
   PubMedGoogle Scholar
• Taniguchi H, Yamamoto H, Hirata T, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005;24(53):7946-52
   PubMed Web of Science ®Google Scholar
• Forget MA, Turcotte S, Beauseigle D, et al. The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 2007;96(4):646-53
   PubMed Web of Science ®Google Scholar
• Xu WH, Liu ZB, Yang C, et al. Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype. PLoS One 2012;7(5):e37624
   Google Scholar
• Wang S, Zhang S. Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. Clin Exp Metastasis 2011;28(6):581-91
   Google Scholar
• Tung EK, Mak CK, Fatima S, et al. Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int 2011;31(10):1494-504
   Google Scholar
• Sato N, Yamabuki T, Takano A, et al. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res 2010;70(13):5326-36
   PubMed Web of Science ®Google Scholar
• Mao B, Niehrs C. Kremen2 modulates Dickkopf2 activity during Wnt/LRP6 signaling. Gene 2003;302(1-2):179-83
   PubMedGoogle Scholar
• Pendas-Franco N, Garcia JM, Pena C, et al. DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1alpha,25-dihydroxyvitamin D3. Oncogene 2008;27(32):4467-77
   Google Scholar
• Yu B, Yang X, Xu Y, et al. Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol 2009;50(5):948-57
   Web of Science ®Google Scholar
• Hoang BH, Kubo T, Healey JH, et al. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004;64(8):2734-9
   PubMedGoogle Scholar
• Yue W, Sun Q, Dacic S, et al. Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer. Carcinogenesis 2008;29(1):84-92
   Google Scholar
• Lee EJ, Jo M, Rho SB, et al. Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Int J Cancer 2009;124(2):287-97
   PubMedGoogle Scholar
• Patil MA, Chua MS, Pan KH, et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 2005;24(23):3737-47
   Google Scholar
• Sheng SL, Huang G, Yu B, Qin WX. Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem 2009;55(9):1656-64
   PubMed Web of Science ®Google Scholar
• Lee HS, Lee HE, Park DJ, et al. Clinical significance of serum and tissue Dickkopf-1 levels in patients with gastric cancer. Clin Chim Acta 2012;413(21-22):1753-60
   PubMed Web of Science ®Google Scholar
• Jiang T, Wang S, Huang L, Zhang S. Clinical significance of serum DKK-1 in patients with gynecological cancer. Int J Gynecol Cancer 2009;19(7):1177-81
   PubMed Web of Science ®Google Scholar
• Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 2012;13(8):817-26
   PubMed Web of Science ®Google Scholar
• Yamabuki T, Takano A, Hayama S, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007;67(6):2517-25
   PubMed Web of Science ®Google Scholar
• Taura N, Yatsuhashi H, Hamasaki K, et al. Increasing hepatitis C virus-associated hepatocellular carcinoma mortality and aging: long term trends in Japan. Hepatol Res 2006;34(2):130-4
   Google Scholar
• Hsu HC, Jeng YM, Mao TL, et al. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157(3):763-70
   Web of Science ®Google Scholar
• Hiotis SP, Rahbari NN, Villanueva GA, et al. Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol 2012;12:64
   Google Scholar
• Kim W, Oe Lim S, et al. Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma. Clin Cancer Res 2003;9(15):5493-500
   PubMed Web of Science ®Google Scholar
• Lee CF, Ling ZQ, Zhao T, Lee KR. Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma. World J Gastroenterol 2008;14(39):6072-7
   Google Scholar
• Iizuka N, Oka M, Yamada-Okabe H, et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 2002;62(14):3939-44
   PubMed Web of Science ®Google Scholar
• Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001;61(5):2129-37
   PubMed Web of Science ®Google Scholar
• Nomura F, Ishijima M, Horikoshi A, et al. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. Am J Gastroenterol 1996;91(7):1380-3
   PubMed Web of Science ®Google Scholar
• Shimauchi Y, Tanaka M, Kuromatsu R, et al. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep 2000;7(2):249-56
   Google Scholar
• Fujiyama S, Tanaka M, Maeda S, et al. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002;62(Suppl 1):57-63
   PubMedGoogle Scholar
• Okuda H, Nakanishi T, Takatsu K, et al. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 2002;17(7):772-8
   Google Scholar
• Okuda H, Saito A, Haruyama K, et al. Unique clinicopathological features of patients with primary malignant hepatic tumors who are seropositive for lectin-reactive alpha-fetoprotein alone: report of five cases. J Gastroenterol Hepatol 2004;19(1):113-14
   Google Scholar
• Okuda H, Saito A, Shiratori K, et al. Clinicopathologic features of patients with primary malignant hepatic tumors seropositive for alpha-fetoprotein-L3 alone in comparison with other patients seropositive for alpha-fetoprotein-L3. J Gastroenterol Hepatol 2005;20(5):759-64
   Google Scholar
• Sterling RK, Jeffers L, Gordon F, et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009;7(1):104-13
   PubMed Web of Science ®Google Scholar
• Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137(1):110-18
   PubMed Web of Science ®Google Scholar
• Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 2007;52(3):776-82
   PubMed Web of Science ®Google Scholar
• Tang W, Miki K, Kokudo N, et al. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma. Int J Oncol 2003;22(5):969-75
   Google Scholar
• Hamamura K, Shiratori Y, Shiina S, et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000;88(7):1557-64
   Google Scholar
• Gotoh M, Nakatani T, Masuda T, et al. Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and des-gamma-carboxyprothrombin. Jpn J Clin Oncol 2003;33(10):522-6
   Google Scholar
• Tang W, Kokudo N, Sugawara Y, et al. Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: association with survival of patients with resectable hepatocellular carcinoma. Oncol Rep 2005;13(1):25-30
   Google Scholar
• Ji J, Yamashita T, Wang XW. Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell Biosci 2011;1(1):4
   PubMedGoogle Scholar
• Xu J, Zhu X, Wu L, et al. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/beta-catenin pathway. Liver Int 2012;32(5):752-60
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wei W, Cheng N, et al.Hepatitis C. Virus-induced upregulation of miR-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012;56(5):1631-40
   PubMed Web of Science ®Google Scholar
• Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008;47(6):1955-63
   PubMed Web of Science ®Google Scholar
• Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004;432(7014):226-30
   PubMed Web of Science ®Google Scholar
• Kapinas K, Kessler C, Ricks T, et al. miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem 2010;285(33):25221-31
   PubMed Web of Science ®Google Scholar
• Baron R, Rawadi G, Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol 2006;76:103-27
   PubMed Web of Science ®Google Scholar
• Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 2008;42(4):669-80
   PubMed Web of Science ®Google Scholar
• Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008;80(6):490-4
   PubMed Web of Science ®Google Scholar
• Politou MC, Heath DJ, Rahemtulla A, et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006;119(7):1728-31
   PubMed Web of Science ®Google Scholar
• Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349(26):2483-94
   PubMed Web of Science ®Google Scholar
• Heider U, Kaiser M, Mieth M, et al. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 2009;82(1):31-8
   Google Scholar
• Voorzanger-Rousselot N, Goehrig D, Journe F, et al. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007;97(7):964-70
   PubMed Web of Science ®Google Scholar
• Katyal S, Oliver JH 3rd, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000;216(3):698-703
   PubMed Web of Science ®Google Scholar
• Kemik O, Kemik AS, Sumer A, et al. Relationship between clinicopathologic variables and serum and tissue levels of dickkopf-1 in patients with rectal cancer. J Investig Med 2011;59(6):947-50
   Google Scholar
• Lee HS, Lee HE, Park do J, et al. Clinical significance of serum and tissue Dickkopf-1 levels in patients with gastric cancer. Clin Chim Acta 2012;413(21-22):1753-60
   PubMed Web of Science ®Google Scholar
• Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009;114(2):371-9
   PubMed Web of Science ®Google Scholar
• Qian J, Zheng Y, Zheng C, et al. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood 2012;119(1):161-9
   PubMed Web of Science ®Google Scholar
• Yang B, Du Z, Gao YT, et al. Methylation of Dickkopf-3 as a prognostic factor in cirrhosis-related hepatocellular carcinoma. World J Gastroenterol 2010;16(6):755-63
   Google Scholar
• Sato H, Suzuki H, Toyota M, et al. Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis 2007;28(12):2459-66
   PubMed Web of Science ®Google Scholar
• Hirata H, Hinoda Y, Nakajima K, et al. Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin Cancer Res 2009;15(18):5678-87
   Google Scholar
• Zhu J, Zhang S, Gu L, Di W. Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma. Carcinogenesis 2012;33(12):2334-43
   Google Scholar
• Tsuji T, Miyazaki M, Sakaguchi M, et al. A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines. Biochem Biophys Res Commun 2000;268(1):20-4
   PubMed Web of Science ®Google Scholar
• Hsieh SY, Hsieh PS, Chiu CT, Chen WY. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 2004;23(57):9183-9
   PubMedGoogle Scholar
• Calvisi DF, Ladu S, Gorden A, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007;117(9):2713-22
   PubMed Web of Science ®Google Scholar
• Gu YM, Ma YH, Zhao WG, Chen J. Dickkopf3 overexpression inhibits pancreatic cancer cell growth in vitro. World J Gastroenterol 2011;17(33):3810-17
   Google Scholar
• Veeck J, Wild PJ, Fuchs T, et al. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer 2009;9:217
   Google Scholar
• Yu J, Tao Q, Cheng YY, et al. Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer 2009;115(1):49-60
   PubMed Web of Science ®Google Scholar
• Licchesi JD, Westra WH, Hooker CM, et al. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 2008;29(5):895-904
   Google Scholar
• Untergasser G, Steurer M, Zimmermann M, et al. The Dickkopf-homolog 3 is expressed in tumor endothelial cells and supports capillary formation. Int J Cancer 2008;122(7):1539-47
   Google Scholar
• Zitt M, Untergasser G, Amberger A, et al. Dickkopf-3 as a new potential marker for neoangiogenesis in colorectal cancer: expression in cancer tissue and adjacent non-cancerous tissue. Dis Markers 2008;24(2):101-9
   Google Scholar
• Fong D, Hermann M, Untergasser G, et al. Dkk-3 expression in the tumor endothelium: a novel prognostic marker of pancreatic adenocarcinomas. Cancer Sci 2009;100(8):1414-20
   Google Scholar
• Jiang T, Huang L, Wang S, Zhang S. Clinical significance of serum Dkk-3 in patients with gynecological cancer. J Obstet Gynaecol Res 2010;36(4):769-73
   Google Scholar
• Zenzmaier C, Heitz M, Klocker H, et al. Elevated levels of Dickkopf-related protein 3 in seminal plasma of prostate cancer patients. J Transl Med 2011;9:193
   Google Scholar
• Zenzmaier C, Untergasser G, Hermann M, et al. Dysregulation of Dkk-3 expression in benign and malignant prostatic tissue. Prostate 2008;68(5):540-7
   Google Scholar
• Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61(4):1659-65
   PubMed Web of Science ®Google Scholar
• Kloten V, Becker B, Winner K, et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res 2013;15(1):R4
   PubMed Web of Science ®Google Scholar
• Urakami S, Shiina H, Enokida H, et al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 2006;12(23):6989-97
   PubMed Web of Science ®Google Scholar
• Liu JB, Qiang FL, Dong J, et al. Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma. World J Gastroenterol 2011;17(44):4917-21
   PubMed Web of Science ®Google Scholar
• Fatima S, Lee NP, Tsang FH, et al. Dickkopf 4 (DKK4) acts on Wnt/beta-catenin pathway by influencing beta-catenin in hepatocellular carcinoma. Oncogene 2012;31(38):4233-44
   Web of Science ®Google Scholar
• Matsui A, Yamaguchi T, Maekawa S, et al. DICKKOPF-4 and -2 genes are upregulated in human colorectal cancer. Cancer Sci 2009;100(10):1923-30
   Google Scholar
• Baehs S, Herbst A, Thieme SE, et al. Dickkopf-4 is frequently down-regulated and inhibits growth of colorectal cancer cells. Cancer Lett 2009;276(2):152-9
   Google Scholar
• Hirata H, Hinoda Y, Majid S, et al. DICKKOPF-4 activates the noncanonical c-Jun-NH2 kinase signaling pathway while inhibiting the Wnt-canonical pathway in human renal cell carcinoma. Cancer 2011;117(8):1649-60
   Google Scholar
• Xi Y, Formentini A, Nakajima G, et al. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer. Oncol Rep 2008;19(1):257-62
   PubMed Web of Science ®Google Scholar
• Ebert MP, Tanzer M, Balluff B, et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N Engl J Med 2012;366(1):44-53
   PubMed Web of Science ®Google Scholar
• Noda T, Nagano H, Takemasa I, et al. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 2009;100(10):1647-58
   PubMed Web of Science ®Google Scholar
• Nagano H, Miyamoto A, Wada H, et al. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 2007;110(11):2493-501
   Google Scholar
• Gambarin-Gelwan M, Wolf DC, Shapiro R, et al. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 2000;95(6):1535-8
   Google Scholar
• Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006;101(9):2038-43
   PubMed Web of Science ®Google Scholar
• Yamashiki N, Sugawara Y, Tamura S, et al. Diagnostic accuracy of alpha-fetoprotein and des-gamma-carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates. Hepatol Res 2011;41(12):1199-207
   Google Scholar
• Liu H, Li P, Zhai Y, et al. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 2010;16(35):4410-15
   Web of Science ®Google Scholar